At last week's joint meeting of the Endocrinologic and Metabolic Drugs and the Drug Safety and Risk Management advisory committees on Avandia rosiglitazone, the returning panel members had more confidence in the drug's safety after they reviewed readjudicated data from the RECORD trial than they did at a 2010 meeting. The three returning panel members who voted to withdraw the drug in 2010 all voted to keep Avandia on the market at last week's meeting, with two of the three voting to relax the REMS requirements and the third voting to keep the REMS as is. Among